Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>> Download now...

Bayer Given China Approval for Nexavar

publication date: Jul 28, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals were awarded SFDA approval for Nexavar® (sorafenib) tablets, a treatment for unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer. The approval was based on two international Phase III trials that showed Nexavar improved overall survival in liver cancer patients. More details...

Stock Symbol: (NYSE: ONYX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

China Pharmaceutical R&D Summit
April 23-26, 2012
Shanghai, China


Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China


Vaccines China 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners